About Jamil Beg
Jamil Beg is a director at AdvanCell.
Form D filings also name Jamil Beg as a director at Kinaset Therapeutics.
Jamil Beg first appears on SEC filings in 2020.
Experience
This experience comes from Jamil Beg's profile and from SEC filings. For roles taken from filings, the years are when the filings name Jamil Beg in the role, so the role may have started earlier or lasted longer.
AdvanCell, Inc. Current
Chair of Audit Committee
2025 – Present · Cambridge, MA
Develops targeted radiation treatments for people with cancer.
SI
SV Health Investors Current
Partner
2024 – Present
RB
Renasant Bio Current
Founding Investor
2022 – Present
Kinaset Therapeutics, Inc. Current
Founding Investor (2020 – Present)
Director
2020 – Present · Medfield, MA
NB
Nido Biosciences Current
Founder
2018 – Present
5V
5AM Ventures
Partner
2017 – 2023
TS
The Wharton School
Guest Lecturer
2019 – 2022
RA
Rallybio
Board Observer
2018 – 2021
MA
MassChallenge
Mentor
2017 – 2021
TG
The BioBreak Group
Board Member
2007 – 2021
AK
Akouos
Board Observer
2017 – 2020
AA
Aprea AB
Board Observer
2017 – 2018
ST
SAGE Therapeutics
Senior Director, Business Development & Brand Leader
2012 – 2017
Key Colleagues at Startups
The people Jamil Beg works with at each company, as listed on that company's latest Form D.
AdvanCell, Inc. · Form D, Jul 16, 2026
AK
Andrew Kay
Director
PL
Philina Lee
Chief Executive Officer and director
KC
Kevin Cameron
Director
CG
Christopher Gagliardi
Director
BM
Bali Muralidhar
Director
WL
Wing Cheong Lam
Director
AA
Andrew Adamovich
Founder & Managing Director, Australia
AP
Aaron Pickett
Secretary
NE
Nik Economopoulos
Director
AA
Anthony Aiudi
Director
Kinaset Therapeutics, Inc. · Form D/A, Jul 17, 2023
TK
Tom King
Director
RC
Robert Clarke
Chief Executive Officer and director
BV
Bram Vanparys
Director
FM
Frazer Morgan
Chief Development Officer
KB
Kevin Bitterman
Director
RH
Roger Heerman
Chief Business Officer and Chief Operating Officer